No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Drugmaker GSK said on Tuesday that Exdensur (depemokimab), an ultra-long-acting biologic to treat respiratory diseases, has received marketing authorisation from the UK's Medicines and Healthcare products Regulatory Agency.
GSK said Exdensur has now been approved in two indications - as an add-on maintenance treatment of asthma in adult and adolescent patients aged 12 years and older with type 2 inflammation, and as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe chronic rhinosinusitis with nasal polyps.
The FTSE 100-listed firm said the approval was based on data from its SWIFT and ANCHOR phase III trials, which showed "sustained efficacy" with a twice-yearly dosing regimen for depemokimab.
Each of the four trials met their primary or co-primary endpoints with "statistically significant and clinically meaningful" results, comparing the addition of depemokimab to standard of care versus standard of care alone.
GSK's Kaivan Khavandi said: "Today's UK approval of Exdensur, the first in the world, has the potential to redefine care for millions of patients. This ultra-long-acting biologic delivers sustained efficacy to reduce asthma exacerbations, keep patients out of hospital and help prevent cumulative lung damage in just two doses a year. This is a step change in respiratory treatment, and we look forward to additional regulatory decisions expected in the US, Japan, EU and China."
Reporting by Iain Gilbert at Sharecast.com
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.